Critical Role of the Potential O-Linked Glycosylation Sites of CXCR4 in Cell Migration and Bone Marrow Homing of Hematopoietic Stem Progenitor Cells

Medicine, Basic Medical Sciences, Hematology, Life Sciences, Cell Biology, Biochemistry, Immunology,
CXCR4   O-linked glycosylation   hematopoietic stem progenitor cells   cell migration   bone marrow homing   glycosylation   CXCL12  

1. Academic Background and Research Origin Hematopoietic stem/progenitor cells (HSPCs) are the foundation for maintaining the steady state of the adult blood system. Every day, the human body needs to generate billions of new blood cells—a process that relies on the capacity of HSPCs for self-renewal and directed differentiation within the bone mar...

Inflammatory Pathways and the Bone Marrow Microenvironment in Inherited Bone Marrow Failure Syndromes

Medicine, Pediatrics, Basic Medical Sciences, Hematology, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology, Genetics,
inherited bone marrow failure syndromes   inflammation   pro-inflammatory cytokines   bone marrow microenvironment   mesenchymal stromal cells   hematopoietic stem cells   cytokine network  

Inflammatory Pathways and Bone Marrow Microenvironment in Inherited Bone Marrow Failure Syndromes: New Insights into Chronic Inflammation Research Background and Academic Significance Inherited bone marrow failure syndromes (IBMFS) are a group of genetic disorders characterized by reduced hematopoietic cell production due to blood stem cell dysfunc...

RUNX1 is a Key Inducer of Human Hematopoiesis Controlling Non-Hematopoietic Mesodermal Development

Medicine, Basic Medical Sciences, Hematology, Oncology, Life Sciences, Cell Biology, Biochemistry, Genetics,
RUNX1   hematopoiesis   non-hematopoietic mesoderm   mesenchymal cells   transcription factor   human development   stem cell differentiation  

The Dominant Role of RUNX1 in Human Hematopoietic Development and Mesodermal Fate Balance — An Interpretation of “runx1 is a key inducer of human hematopoiesis controlling non-hematopoietic mesodermal development” 1. Academic Background and Research Motivation The development of the hematopoietic system is fundamental for the growth and maintenance...

Modulation of Bone Marrow Haematopoietic Stem Cell Activity as a Therapeutic Strategy After Myocardial Infarction: A Preclinical Study

Medicine, Hematology, Cardiovascular System, Life Sciences, Cell Biology, Immunology,
myocardial infarction   bone marrow haematopoietic stem cells   inflammation   vitamin A metabolites   cardiac function  

Academic Background Myocardial Infarction (MI) is one of the major global health concerns. Although myeloid cells in the bone marrow (BM) are crucial for tissue repair after MI, excessive myelopoiesis can exacerbate scarring and impair cardiac function. Hematopoietic stem cells (HSCs) in the bone marrow possess unique regenerative capabilities, ena...

Selective Translational Control by PABPC1 Phase Separation Regulates Blast Crisis and Therapy Resistance in Chronic Myeloid Leukaemia

Medicine, Hematology, Oncology, Life Sciences, Cell Biology, Biochemistry,
Chronic Myeloid Leukaemia   PABPC1   Phase Separation   Translational Control   Therapy Resistance   Blast Crisis   CRISPR-Cas9 Screening  

Academic Background and Problem Introduction Chronic Myeloid Leukemia (CML) is a hematologic malignancy driven by the BCR-ABL1 fusion gene. Although Tyrosine Kinase Inhibitors (TKIs) have significantly improved the survival rate of CML patients, TKI resistance and disease progression to the blast crisis (BC) phase remain major challenges in clinica...

Odronextamab Monotherapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: Primary Efficacy and Safety Analysis in Phase 2 ELM-2 Trial

Medicine, Hematology, Oncology, Life Sciences, Immunology,
Diffuse Large B Cell Lymphoma   Relapsed/Refractory   Odronextamab   ELM-2 Trial   Safety   Efficacy   Cytokine Release Syndrome  

Academic Background Diffuse Large B Cell Lymphoma (DLBCL) is an aggressive form of B-cell non-Hodgkin lymphoma (B-NHL), accounting for approximately 30% of all non-Hodgkin lymphomas. Although first-line immunochemotherapy (e.g., R-CHOP regimen) has shown efficacy in DLBCL patients, about 30% of patients relapse or become refractory (relapsed/refrac...